project id: TCGA-PRAD; case submitter id: TCGA-EJ-A7NJ; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.77; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.71; rna integrity number: 9.0; age at index: 59; days to birth: -21748; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1954; age at diagnosis: 21748; ajcc clinical m: M0; ajcc clinical t: T2c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 197.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 211; initial weight: 250.0; sample id: b13d4e3d-898e-4339-a506-110b8e803b6e; sample submitter id: TCGA-EJ-A7NJ-01A; portion id: 4ba77eac-554e-4616-81c9-e1d8c21acd4c; portion submitter id: TCGA-EJ-A7NJ-01A-22; slide id: 4c0c0d53-2632-4a64-b96e-354212a93c9e; slide submitter id: TCGA-EJ-A7NJ-01A-02-TSB; percent lymphocyte infiltration: 20.0; percent monocyte infiltration: 0.0; percent necrosis: 2.0; percent neutrophil infiltration: 0.0; percent normal cells: 20.0; percent stromal cells: 35.0; percent tumor cells: 43.0; percent tumor nuclei: 60.0; section location: TOP;